A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(29 sites)

United States

City of Hope, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

University of California San Francisco, San Francisco, California

Colorado Blood Cancer Institute, Denver, Colorado

Icahn School of Medicine at Mt. Sinai, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Levine Cancer Institute, Charlotte, North Carolina

University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

MD Anderson Cancer Center, Houston, Texas

Belgium

UZ Antwerpen, Edegem

UZ Gent, Ghent

CHU de Liege, Liège

France

CHU Nantes, Nantes

CHU Lyon Sud, Pierre-Bénite

Chu Rennes Hopital Pontchaillou, Rennes

Institut Claudius Regaud, Toulouse

Japan

Japanese Red Cross Medical Center, Shibuya City

Osaka University Hospital, Suita-shi

The Cancer Institute Hospital of JFCR, Tokyo

Netherlands

VUMC Amsterdam, Amsterdam

Universitair Medisch Centrum Groningen, Groningen

UMC Utrecht, Utrecht

Spain

Hosp. Univ. Germans Trias I Pujol, Badalona

Hosp Clinic de Barcelona, Barcelona

Hosp Univ Fund Jimenez Diaz, Madrid

Clinica Univ. de Navarra, Pamplona

Hosp Clinico Univ de Salamanca, Salamanca

United Kingdom

University College Hospital, London

Royal Marsden Hospital, Sutton